Hrt Financial LP Bristol Myers Squibb CO Transaction History

Hrt Financial LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$48.48 - $57.85 $10.7 Million - $12.8 Million	221,739 New	221,739 $11.4 Million
Q2 2023 Aug 11, 2023	BUY	$63.71 - $70.74 $14.6 Million - $16.2 Million	229,452 New	229,452 $14.7 Million
Q4 2022 Feb 10, 2023	BUY	$68.48 - $81.09 $5.18 Million - $6.14 Million	75,662 New	75,662 $5.44 Million
Q2 2022 Aug 12, 2022	SELL	$72.62 - $79.98 $20.3 Million - $22.4 Million	-279,862 Reduced 90.16%	30,539 $2.35 Million
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $19.1 Million - $22.9 Million	310,401 New	310,401 $22.7 Million
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $18 Million - $21 Million	-303,393 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$61.91 - $67.42 $4.36 Million - $4.75 Million	70,388 Added 30.21%	303,393 $20.3 Million
Q1 2021 May 17, 2021	BUY	$59.34 - $66.74 $10.3 Million - $11.6 Million	174,274 Added 296.73%	233,005 $14.7 Million
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $3.39 Million - $3.84 Million	58,731 New	58,731 $3.64 Million
Q3 2020 Nov 13, 2020	SELL	$57.43 - $63.64 $37.9 Million - $42 Million	-660,374 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$54.82 - $64.09 $36.2 Million - $42.3 Million	660,374 New	660,374 $38.8 Million

2,425

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.